NEW ORLEANS, April 13, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Patterson Companies, Inc. (NasdaqGS:PDCO), if they purchased the Company’s shares between June 26, 2015 and February 28, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Minnesota.
Get Help
Patterson investors should visit us at https://www.claimsfiler.com/cases/view-patterson-companies-inc-securities-litigation-1 or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Patterson and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 12, 2018, the Federal Trade Commission disclosed that it had filed a complaint against the Company for violating antitrust regulations through a conspiracy with other dental supply companies to fix the prices of dental products and refuse to offer discounts or service to buying groups representing dental practitioners. Then, on March 1, 2018, the Company revealed dismal financial results for 2018Q3 and the departure of its Chief Financial Officer.
On this news, the price of Patterson’s shares plummeted $7.48 per share, or 23% in one day.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.


Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
FTC Questions Apple News Over Alleged Bias Against Conservative Media
How Marco Pharma International Preserves German Homeopathic Traditions in America
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 



